Guat65的个人主页 - 老虎社区

Guat65

Guat65

暂无个人介绍

IP属地：未知

4关注

0粉丝

0主题

0勋章

2021-12-28

How

Rivian's First Earnings Report Looks Like Tesla's Early Days, But Here's What's Different

2021-12-22

Great ariticle, would you like to share it?

@OptionPlus:期权复盘：圣诞行情或迟不缺，别错过苹果、特斯拉最佳卖权期！

2021-12-22

Go

@Buy_Sell:🚀【12月21日】新能源汽车股重挫，热门中概普跌，今天买点啥？

2021-06-17

Haj

ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst

2021-06-17

Has

抱歉，原内容已删除

2021-04-13

Gd

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3569745941427325","uuid":"3569745941427325","gmtCreate":1606792870727,"gmtModify":1618367903670,"name":"Guat65","pinyin":"guat65","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/93d2135fbec26685c7a7aa6e923c9ac3","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":4,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.16%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":696856888,"gmtCreate":1640668818075,"gmtModify":1640669323692,"author":{"id":"3569745941427325","authorId":"3569745941427325","name":"Guat65","avatar":"https://static.tigerbbs.com/93d2135fbec26685c7a7aa6e923c9ac3","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569745941427325","authorIdStr":"3569745941427325"},"themes":[],"htmlText":"How&nbsp;","listText":"How&nbsp;","text":"How","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696856888","repostId":"1155676290","repostType":4,"repost":{"id":"1155676290","kind":"news","pubTimestamp":1640662411,"share":"https://www.laohu8.com/m/news/1155676290?lang=&edition=full","pubTime":"2021-12-28 11:33","market":"us","language":"en","title":"Rivian's First Earnings Report Looks Like Tesla's Early Days, But Here's What's Different","url":"https://stock-news.laohu8.com/highlight/detail?id=1155676290","media":"Motley Fool","summary":"On Dec. 16, high-end electric pickup and SUV maker Rivian Automotive(NASDAQ:RIVN)reported its first-","content":"<p>On Dec. 16, high-end electric pickup and SUV maker&nbsp;<b>Rivian Automotive</b>(NASDAQ:RIVN)reported its first-ever quarterly results since going public through its recent IPO. The company delivered 11 electric vehicles (EVs) in total during the third quarter of 2021, bringing in approximately $1 million in revenue. Meanwhile, its market capitalization (market cap) was a princely $100 billion at the time of the quarterly release. Overall, the company looks a lot like&nbsp;<b>Tesla</b>(NASDAQ:TSLA)shortly after it went public, but there are some key differences sounding a note of caution.</p>\n<p><b>Rivian is a mirror of Tesla in some ways</b></p>\n<p>Once investors got a look at Rivian's Q3 earnings report,its share price dropped sharply, bringing its market cap down from $100 billion to a pre-Christmas level of $88 billion. Some analysts have been looking at Rivian's current position and arguing that it's quite similar to Tesla's at the start of its own upward climb. That was when Elon Musk's company also had scant revenue and little more than a few vehicle models and projections of future production to give it stock market traction.</p>\n<p>According to Rivian management's letter to shareholders, the company earned just $1 million in revenue during the three months ending on Sept. 30. Its net loss for the period was $1.23 billion, though $458 million of this was a net loss due to convertible notes. This led to a $12.21 net loss per share, far worse than Wall Street analyst consensus predictions of a $6.68 loss per share. Omitting the convertible notes, the company's quarterly net loss was $776 million.</p>\n<p>While current production is only a handful of vehicles, Rivian is looking to the future as a cause for optimism. It ended the quarter with $5.2 billion in cash; together with the net proceeds from its $13.7 billion in gross IPO proceeds and other, smaller funding sources, says it has around $19.9 billion to work with in achieving its goals. Those goals include boosting its Illinois factory's manufacturing capacity from 150,000 to 200,000 vehicles annually, along with building a second factory in Georgia with a 400,000-vehicle manufacturing capacity, to begin operating in 2024.</p>\n<p>These metrics and goals appear attractive, but at this point, they are mostly speculation. Rivian has 71,000 pre-orders for its R1T pickup truck, but it only has a tiny handful of vehicles actually on the road. Going from producing 11 vehicles in a quarter to, theoretically, 150,000 per quarter (based on Rivian's factory estimates) in just three years is a steep challenge even with around $20 billion available to fund it. While the sum is almost two-thirds of the amount automotive giant&nbsp;<b>Ford</b>(NYSE:F)is spending on its own EV production, the Blue Oval has been an established automaker for over a century, giving it deep levels of knowledge on mass production and immense resources of machinery, technical staff, and name recognition among consumers around the globe.</p>\n<p>Rivian may also have lost Ford's technical assistance after the latter decided to \"go it alone\" on its EV program in November, canceling its joint EV production plans with Rivian. Another serious roadblock Rivian will have to overcome is the very different environment it faces as an EV start-up compared to Tesla a decade ago.</p>\n<p><b>Where Rivian's road forks away from Tesla's</b></p>\n<p>While Rivian's current metrics look rather like Tesla's early days except for its massive valuation, it isn't operating in the same environment. Though hybrid vehicles existed well before it, and EVs had been tried, Tesla was a groundbreaking enterprise, the first of its kind.</p>\n<p>Rivian is operating in a very different world. Tesla itself is now a dominating force with a market cap above $1 trillion, manufacturing around a million very popular EVs per year. Ford recently&nbsp;stopped accepting reservations for its upcoming F-150 Lightningelectric pickup at 200,000 trucks&nbsp;because production couldn't keep up with demand. It's also building $30 billion worth of EV and EV battery facilities by 2025 for a massive manufacturing expansion.</p>\n<p>Chinese EV manufacturer&nbsp;<b>Nio</b>(NYSE:NIO)just unveiled a mid-sized electric sedan, the ET5, capable of challenging the Tesla Model S Plaid on range and features, and it plans to expand into 25 countries over the next few years. It's also now consistently building more than 10,000 vehicles per month. Just about every major automaker in the world is in the process of rolling out electric vehicles, and there are many other dedicated EV start-ups to contend with, too.</p>\n<p>In short, while Rivian resembles early Tesla, Tesla was operating with close-to-zero serious competition, giving it much more leeway as a pioneer. Rivian, by contrast, is trying to break into an EV market already crowded with successful rivals, who are busy expanding production into the hundreds of thousands and then millions, while Rivian is still trying to get its first few vehicles sold.</p>\n<p>On the plus side, Rivian does at least produce working vehicles and has&nbsp;preorders for 71,000 R1T pickup trucks.&nbsp;Retail titan&nbsp;<b>Amazon</b>(NASDAQ:AMZN)is working with it to buy a potential 100,000 delivery vans. Actually producing these vehicles could be a problem, however, considering that Ford may no longer be a manufacturing partner. In a recent CNBC interview, Ford CEO Jim Farley said Ford is considering&nbsp;selling its 12% stake in Rivianonce lock-up expires, gaining billions it can return to shareholders or invest in its own rapidly accelerating EV push.</p>\n<p><b>Buy Rivian now, or await a lower entry point?</b></p>\n<p>Orders and sheer market enthusiasm for all EV stocks are arguably the two main factors holding Rivian's share price relatively high right now. Nevertheless, in my opinion, the hurdles and risks it faces in maintaining or growing this valuation are quite high. The challenges of ramping up production (possibly without Ford's know-how and assistance), the numerous powerful competitors it faces, and the likelihood Ford will sell its Rivian stake, make me skeptical it will maintain its current stock value much longer.</p>\n<p>Rivian may become a viable&nbsp;electric car stock&nbsp;long-term, but it seems likely to shed a lot of its current soaring valuation in the meantime. This scenario makes waiting for a much lower share price as an entry point a strategy at least worth considering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rivian's First Earnings Report Looks Like Tesla's Early Days, But Here's What's Different</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRivian's First Earnings Report Looks Like Tesla's Early Days, But Here's What's Different\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-28 11:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/27/rivian-earnings-report-looks-like-tesla-early-days/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Dec. 16, high-end electric pickup and SUV maker Rivian Automotive(NASDAQ:RIVN)reported its first-ever quarterly results since going public through its recent IPO. The company delivered 11 electric ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/27/rivian-earnings-report-looks-like-tesla-early-days/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","RIVN":"Rivian Automotive, Inc."},"source_url":"https://www.fool.com/investing/2021/12/27/rivian-earnings-report-looks-like-tesla-early-days/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155676290","content_text":"On Dec. 16, high-end electric pickup and SUV maker Rivian Automotive(NASDAQ:RIVN)reported its first-ever quarterly results since going public through its recent IPO. The company delivered 11 electric vehicles (EVs) in total during the third quarter of 2021, bringing in approximately $1 million in revenue. Meanwhile, its market capitalization (market cap) was a princely $100 billion at the time of the quarterly release. Overall, the company looks a lot like Tesla(NASDAQ:TSLA)shortly after it went public, but there are some key differences sounding a note of caution.\nRivian is a mirror of Tesla in some ways\nOnce investors got a look at Rivian's Q3 earnings report,its share price dropped sharply, bringing its market cap down from $100 billion to a pre-Christmas level of $88 billion. Some analysts have been looking at Rivian's current position and arguing that it's quite similar to Tesla's at the start of its own upward climb. That was when Elon Musk's company also had scant revenue and little more than a few vehicle models and projections of future production to give it stock market traction.\nAccording to Rivian management's letter to shareholders, the company earned just $1 million in revenue during the three months ending on Sept. 30. Its net loss for the period was $1.23 billion, though $458 million of this was a net loss due to convertible notes. This led to a $12.21 net loss per share, far worse than Wall Street analyst consensus predictions of a $6.68 loss per share. Omitting the convertible notes, the company's quarterly net loss was $776 million.\nWhile current production is only a handful of vehicles, Rivian is looking to the future as a cause for optimism. It ended the quarter with $5.2 billion in cash; together with the net proceeds from its $13.7 billion in gross IPO proceeds and other, smaller funding sources, says it has around $19.9 billion to work with in achieving its goals. Those goals include boosting its Illinois factory's manufacturing capacity from 150,000 to 200,000 vehicles annually, along with building a second factory in Georgia with a 400,000-vehicle manufacturing capacity, to begin operating in 2024.\nThese metrics and goals appear attractive, but at this point, they are mostly speculation. Rivian has 71,000 pre-orders for its R1T pickup truck, but it only has a tiny handful of vehicles actually on the road. Going from producing 11 vehicles in a quarter to, theoretically, 150,000 per quarter (based on Rivian's factory estimates) in just three years is a steep challenge even with around $20 billion available to fund it. While the sum is almost two-thirds of the amount automotive giant Ford(NYSE:F)is spending on its own EV production, the Blue Oval has been an established automaker for over a century, giving it deep levels of knowledge on mass production and immense resources of machinery, technical staff, and name recognition among consumers around the globe.\nRivian may also have lost Ford's technical assistance after the latter decided to \"go it alone\" on its EV program in November, canceling its joint EV production plans with Rivian. Another serious roadblock Rivian will have to overcome is the very different environment it faces as an EV start-up compared to Tesla a decade ago.\nWhere Rivian's road forks away from Tesla's\nWhile Rivian's current metrics look rather like Tesla's early days except for its massive valuation, it isn't operating in the same environment. Though hybrid vehicles existed well before it, and EVs had been tried, Tesla was a groundbreaking enterprise, the first of its kind.\nRivian is operating in a very different world. Tesla itself is now a dominating force with a market cap above $1 trillion, manufacturing around a million very popular EVs per year. Ford recently stopped accepting reservations for its upcoming F-150 Lightningelectric pickup at 200,000 trucks because production couldn't keep up with demand. It's also building $30 billion worth of EV and EV battery facilities by 2025 for a massive manufacturing expansion.\nChinese EV manufacturer Nio(NYSE:NIO)just unveiled a mid-sized electric sedan, the ET5, capable of challenging the Tesla Model S Plaid on range and features, and it plans to expand into 25 countries over the next few years. It's also now consistently building more than 10,000 vehicles per month. Just about every major automaker in the world is in the process of rolling out electric vehicles, and there are many other dedicated EV start-ups to contend with, too.\nIn short, while Rivian resembles early Tesla, Tesla was operating with close-to-zero serious competition, giving it much more leeway as a pioneer. Rivian, by contrast, is trying to break into an EV market already crowded with successful rivals, who are busy expanding production into the hundreds of thousands and then millions, while Rivian is still trying to get its first few vehicles sold.\nOn the plus side, Rivian does at least produce working vehicles and has preorders for 71,000 R1T pickup trucks. Retail titan Amazon(NASDAQ:AMZN)is working with it to buy a potential 100,000 delivery vans. Actually producing these vehicles could be a problem, however, considering that Ford may no longer be a manufacturing partner. In a recent CNBC interview, Ford CEO Jim Farley said Ford is considering selling its 12% stake in Rivianonce lock-up expires, gaining billions it can return to shareholders or invest in its own rapidly accelerating EV push.\nBuy Rivian now, or await a lower entry point?\nOrders and sheer market enthusiasm for all EV stocks are arguably the two main factors holding Rivian's share price relatively high right now. Nevertheless, in my opinion, the hurdles and risks it faces in maintaining or growing this valuation are quite high. The challenges of ramping up production (possibly without Ford's know-how and assistance), the numerous powerful competitors it faces, and the likelihood Ford will sell its Rivian stake, make me skeptical it will maintain its current stock value much longer.\nRivian may become a viable electric car stock long-term, but it seems likely to shed a lot of its current soaring valuation in the meantime. This scenario makes waiting for a much lower share price as an entry point a strategy at least worth considering.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691992243,"gmtCreate":1640110217289,"gmtModify":1640110242149,"author":{"id":"3569745941427325","authorId":"3569745941427325","name":"Guat65","avatar":"https://static.tigerbbs.com/93d2135fbec26685c7a7aa6e923c9ac3","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569745941427325","authorIdStr":"3569745941427325"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691992243","repostId":"693017474","repostType":1,"repost":{"id":693017474,"gmtCreate":1639927544363,"gmtModify":1639928709633,"author":{"id":"3527667591235607","authorId":"3527667591235607","name":"OptionPlus","avatar":"https://static.tigerbbs.com/e8009c23927adcf8b5e1e1d101178392","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667591235607","authorIdStr":"3527667591235607"},"themes":[],"title":"期权复盘：圣诞行情或迟不缺，别错过苹果、特斯拉最佳卖权期！","htmlText":"老虎的朋友们好，最近要赶年底结算工作略忙，每天只有晚上花一点时间看看盘。这两周市场相当精彩，美联储如“期”加速taper，四巫日也如“期”巨震。终于，今年的bad news都陆续落地，接下来圣诞行情还有吗？ 我个人感觉接下来应该有一波还不错的行情，至于多长时间就只能走着看。值得一提的是巴菲特的<a target=\"_blank\" href=\"https://laohu8.com/S/BRK.A\">$伯克希尔(BRK.A)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$</a> ，股价在周中创了新高。现在Brk的市值跟<a target=\"_blank\" href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$</a> 差不多，6500亿美元左右，NVDA是大家眼里一致预期的下一个万亿俱乐部成员，搞不好Berkshire才是，谁知道呢，大可关注起来。我最近关注消费ETF<a target=\"_blank\" href=\"https://laohu8.com/S/XLP\">$消费品指数ETF-SPDR主要消费品(XLP)$</a> ，必须消费品上涨是通胀最直接的反映，自从鲍师傅12月5日直接承认通胀，并暗示可能加速Taper，XLP已经连涨了两周。成分股里面PG、COST、PEP、KO、EL等都过去两周都是逆市新高，短期这个通胀预期已经兑现相当充分，应该要开始回调了。但是通胀也不是一时半会儿能下来的，这几个公司和XLP值得大家明年继续关注，等我过几天开始休假了好好整理一下下消费股。同样是消费ETF，可选消费ETF-XLY就跟必消股ETF-XLP差距非常大，主要原因是AMZN和TSLA两个科技股占比太大，接近40%，如果抛去这两个大成分，下面的HD、MC","listText":"老虎的朋友们好，最近要赶年底结算工作略忙，每天只有晚上花一点时间看看盘。这两周市场相当精彩，美联储如“期”加速taper，四巫日也如“期”巨震。终于，今年的bad news都陆续落地，接下来圣诞行情还有吗？ 我个人感觉接下来应该有一波还不错的行情，至于多长时间就只能走着看。值得一提的是巴菲特的<a target=\"_blank\" href=\"https://laohu8.com/S/BRK.A\">$伯克希尔(BRK.A)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$</a> ，股价在周中创了新高。现在Brk的市值跟<a target=\"_blank\" href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$</a> 差不多，6500亿美元左右，NVDA是大家眼里一致预期的下一个万亿俱乐部成员，搞不好Berkshire才是，谁知道呢，大可关注起来。我最近关注消费ETF<a target=\"_blank\" href=\"https://laohu8.com/S/XLP\">$消费品指数ETF-SPDR主要消费品(XLP)$</a> ，必须消费品上涨是通胀最直接的反映，自从鲍师傅12月5日直接承认通胀，并暗示可能加速Taper，XLP已经连涨了两周。成分股里面PG、COST、PEP、KO、EL等都过去两周都是逆市新高，短期这个通胀预期已经兑现相当充分，应该要开始回调了。但是通胀也不是一时半会儿能下来的，这几个公司和XLP值得大家明年继续关注，等我过几天开始休假了好好整理一下下消费股。同样是消费ETF，可选消费ETF-XLY就跟必消股ETF-XLP差距非常大，主要原因是AMZN和TSLA两个科技股占比太大，接近40%，如果抛去这两个大成分，下面的HD、MC","text":"老虎的朋友们好，最近要赶年底结算工作略忙，每天只有晚上花一点时间看看盘。这两周市场相当精彩，美联储如“期”加速taper，四巫日也如“期”巨震。终于，今年的bad news都陆续落地，接下来圣诞行情还有吗？ 我个人感觉接下来应该有一波还不错的行情，至于多长时间就只能走着看。值得一提的是巴菲特的$伯克希尔(BRK.A)$ $伯克希尔B(BRK.B)$ ，股价在周中创了新高。现在Brk的市值跟$英伟达(NVDA)$ 差不多，6500亿美元左右，NVDA是大家眼里一致预期的下一个万亿俱乐部成员，搞不好Berkshire才是，谁知道呢，大可关注起来。我最近关注消费ETF$消费品指数ETF-SPDR主要消费品(XLP)$ ，必须消费品上涨是通胀最直接的反映，自从鲍师傅12月5日直接承认通胀，并暗示可能加速Taper，XLP已经连涨了两周。成分股里面PG、COST、PEP、KO、EL等都过去两周都是逆市新高，短期这个通胀预期已经兑现相当充分，应该要开始回调了。但是通胀也不是一时半会儿能下来的，这几个公司和XLP值得大家明年继续关注，等我过几天开始休假了好好整理一下下消费股。同样是消费ETF，可选消费ETF-XLY就跟必消股ETF-XLP差距非常大，主要原因是AMZN和TSLA两个科技股占比太大，接近40%，如果抛去这两个大成分，下面的HD、MC","images":[{"img":"https://static.tigerbbs.com/d29067b6581247f9ce35181e23d36380","width":"2188","height":"1150"},{"img":"https://static.tigerbbs.com/7108d9566091f4e2a50fc47a7c5c0619","width":"1282","height":"582"},{"img":"https://static.tigerbbs.com/4137e48e4232db1aaf465714045d6d4a","width":"830","height":"302"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693017474","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":6,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":759,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691996697,"gmtCreate":1640109772365,"gmtModify":1640109772365,"author":{"id":"3569745941427325","authorId":"3569745941427325","name":"Guat65","avatar":"https://static.tigerbbs.com/93d2135fbec26685c7a7aa6e923c9ac3","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569745941427325","authorIdStr":"3569745941427325"},"themes":[],"htmlText":"Go","listText":"Go","text":"Go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691996697","repostId":"693578764","repostType":1,"repost":{"id":693578764,"gmtCreate":1640054724293,"gmtModify":1640056006846,"author":{"id":"3527667596890271","authorId":"3527667596890271","name":"Buy_Sell","avatar":"https://static.tigerbbs.com/a5f0ed79a338c758a22e0b4ea13bf9d2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667596890271","authorIdStr":"3527667596890271"},"themes":[],"title":"🚀【12月21日】新能源汽车股重挫，热门中概普跌，今天买点啥？","htmlText":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 港股三大指数涨跌不一，恒指涨0.22%，国指涨0.07%，恒生科技指数跌0.57%。 盘面上，大型科技股继续下跌，<a href=\"https://laohu8.com/S/09999\">$网易-S(09999)$</a> 跌近3%，<a href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 、<a href=\"https://laohu8.com/S/03690\">$美团-W(03690)$</a> 跌超1%，<a href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 等皆有跌幅；内房股与物管股开盘活跃，生物科技股普涨，<a href=\"https://laohu8.com/S/06160\">$百济神州(06160)$</a> 、<a href=\"https://laohu8.com/S/02269\">$药明生物(02269)$</a> 均高开；啤酒股、乳制品、汽车股、体育用品股、航空股普跌，信义玻璃涨近5%，今年净利润同比增长70%-85%。 美股市场 拜登经济支出计划被推迟审议，美股三大指数集体收跌，纳指跌1.24%，道指跌1.23%，标普500指数跌1.14%。 金融股普遍下行，<a href=\"https://laohu8.com/S/GS\">$高盛(GS)$</a> 跌逾3%，<a href=\"https://laohu8.com/S/WFC\">$富国银行(WFC)$</a> 下跌2.8%，<a href=\"https://laohu8.com/S/JPM\">$摩根大通(JPM)$</a> 和<a href=\"https://laohu8.com/S/BAC\">$美</a>","listText":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 港股三大指数涨跌不一，恒指涨0.22%，国指涨0.07%，恒生科技指数跌0.57%。 盘面上，大型科技股继续下跌，<a href=\"https://laohu8.com/S/09999\">$网易-S(09999)$</a> 跌近3%，<a href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 、<a href=\"https://laohu8.com/S/03690\">$美团-W(03690)$</a> 跌超1%，<a href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 等皆有跌幅；内房股与物管股开盘活跃，生物科技股普涨，<a href=\"https://laohu8.com/S/06160\">$百济神州(06160)$</a> 、<a href=\"https://laohu8.com/S/02269\">$药明生物(02269)$</a> 均高开；啤酒股、乳制品、汽车股、体育用品股、航空股普跌，信义玻璃涨近5%，今年净利润同比增长70%-85%。 美股市场 拜登经济支出计划被推迟审议，美股三大指数集体收跌，纳指跌1.24%，道指跌1.23%，标普500指数跌1.14%。 金融股普遍下行，<a href=\"https://laohu8.com/S/GS\">$高盛(GS)$</a> 跌逾3%，<a href=\"https://laohu8.com/S/WFC\">$富国银行(WFC)$</a> 下跌2.8%，<a href=\"https://laohu8.com/S/JPM\">$摩根大通(JPM)$</a> 和<a href=\"https://laohu8.com/S/BAC\">$美</a>","text":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 港股三大指数涨跌不一，恒指涨0.22%，国指涨0.07%，恒生科技指数跌0.57%。 盘面上，大型科技股继续下跌，$网易-S(09999)$ 跌近3%，$阿里巴巴-SW(09988)$ 、$美团-W(03690)$ 跌超1%，$快手-W(01024)$ 等皆有跌幅；内房股与物管股开盘活跃，生物科技股普涨，$百济神州(06160)$ 、$药明生物(02269)$ 均高开；啤酒股、乳制品、汽车股、体育用品股、航空股普跌，信义玻璃涨近5%，今年净利润同比增长70%-85%。 美股市场 拜登经济支出计划被推迟审议，美股三大指数集体收跌，纳指跌1.24%，道指跌1.23%，标普500指数跌1.14%。 金融股普遍下行，$高盛(GS)$ 跌逾3%，$富国银行(WFC)$ 下跌2.8%，$摩根大通(JPM)$ 和$美","images":[{"img":"https://static.tigerbbs.com/8c224c9889536a14f83eca563ae0bb07","width":"-1","height":"-1"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693578764","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"subType":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1621,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":161826132,"gmtCreate":1623918850626,"gmtModify":1634025889879,"author":{"id":"3569745941427325","authorId":"3569745941427325","name":"Guat65","avatar":"https://static.tigerbbs.com/93d2135fbec26685c7a7aa6e923c9ac3","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569745941427325","authorIdStr":"3569745941427325"},"themes":[],"htmlText":"Haj","listText":"Haj","text":"Haj","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/161826132","repostId":"1103057922","repostType":4,"repost":{"id":"1103057922","kind":"news","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company&nbsp;<b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"tweetType":1,"viewCount":443,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161826377,"gmtCreate":1623918839899,"gmtModify":1634025890000,"author":{"id":"3569745941427325","authorId":"3569745941427325","name":"Guat65","avatar":"https://static.tigerbbs.com/93d2135fbec26685c7a7aa6e923c9ac3","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569745941427325","authorIdStr":"3569745941427325"},"themes":[],"htmlText":"Has","listText":"Has","text":"Has","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161826377","repostId":"2143797875","repostType":4,"isVote":1,"tweetType":1,"viewCount":600,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":345436244,"gmtCreate":1618328351088,"gmtModify":1634293662530,"author":{"id":"3569745941427325","authorId":"3569745941427325","name":"Guat65","avatar":"https://static.tigerbbs.com/93d2135fbec26685c7a7aa6e923c9ac3","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569745941427325","authorIdStr":"3569745941427325"},"themes":[],"htmlText":"Gd","listText":"Gd","text":"Gd","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/345436244","repostId":"1194635432","repostType":4,"isVote":1,"tweetType":1,"viewCount":429,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":345436244,"gmtCreate":1618328351088,"gmtModify":1634293662530,"author":{"id":"3569745941427325","authorId":"3569745941427325","name":"Guat65","avatar":"https://static.tigerbbs.com/93d2135fbec26685c7a7aa6e923c9ac3","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569745941427325","authorIdStr":"3569745941427325"},"themes":[],"htmlText":"Gd","listText":"Gd","text":"Gd","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/345436244","repostId":"1194635432","repostType":4,"isVote":1,"tweetType":1,"viewCount":429,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161826132,"gmtCreate":1623918850626,"gmtModify":1634025889879,"author":{"id":"3569745941427325","authorId":"3569745941427325","name":"Guat65","avatar":"https://static.tigerbbs.com/93d2135fbec26685c7a7aa6e923c9ac3","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569745941427325","authorIdStr":"3569745941427325"},"themes":[],"htmlText":"Haj","listText":"Haj","text":"Haj","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/161826132","repostId":"1103057922","repostType":4,"repost":{"id":"1103057922","kind":"news","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company&nbsp;<b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"tweetType":1,"viewCount":443,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161826377,"gmtCreate":1623918839899,"gmtModify":1634025890000,"author":{"id":"3569745941427325","authorId":"3569745941427325","name":"Guat65","avatar":"https://static.tigerbbs.com/93d2135fbec26685c7a7aa6e923c9ac3","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569745941427325","authorIdStr":"3569745941427325"},"themes":[],"htmlText":"Has","listText":"Has","text":"Has","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161826377","repostId":"2143797875","repostType":4,"isVote":1,"tweetType":1,"viewCount":600,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":696856888,"gmtCreate":1640668818075,"gmtModify":1640669323692,"author":{"id":"3569745941427325","authorId":"3569745941427325","name":"Guat65","avatar":"https://static.tigerbbs.com/93d2135fbec26685c7a7aa6e923c9ac3","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569745941427325","authorIdStr":"3569745941427325"},"themes":[],"htmlText":"How&nbsp;","listText":"How&nbsp;","text":"How","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696856888","repostId":"1155676290","repostType":4,"isVote":1,"tweetType":1,"viewCount":1128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691992243,"gmtCreate":1640110217289,"gmtModify":1640110242149,"author":{"id":"3569745941427325","authorId":"3569745941427325","name":"Guat65","avatar":"https://static.tigerbbs.com/93d2135fbec26685c7a7aa6e923c9ac3","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569745941427325","authorIdStr":"3569745941427325"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691992243","repostId":"693017474","repostType":1,"repost":{"id":693017474,"gmtCreate":1639927544363,"gmtModify":1639928709633,"author":{"id":"3527667591235607","authorId":"3527667591235607","name":"OptionPlus","avatar":"https://static.tigerbbs.com/e8009c23927adcf8b5e1e1d101178392","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667591235607","authorIdStr":"3527667591235607"},"themes":[],"title":"期权复盘：圣诞行情或迟不缺，别错过苹果、特斯拉最佳卖权期！","htmlText":"老虎的朋友们好，最近要赶年底结算工作略忙，每天只有晚上花一点时间看看盘。这两周市场相当精彩，美联储如“期”加速taper，四巫日也如“期”巨震。终于，今年的bad news都陆续落地，接下来圣诞行情还有吗？ 我个人感觉接下来应该有一波还不错的行情，至于多长时间就只能走着看。值得一提的是巴菲特的<a target=\"_blank\" href=\"https://laohu8.com/S/BRK.A\">$伯克希尔(BRK.A)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$</a> ，股价在周中创了新高。现在Brk的市值跟<a target=\"_blank\" href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$</a> 差不多，6500亿美元左右，NVDA是大家眼里一致预期的下一个万亿俱乐部成员，搞不好Berkshire才是，谁知道呢，大可关注起来。我最近关注消费ETF<a target=\"_blank\" href=\"https://laohu8.com/S/XLP\">$消费品指数ETF-SPDR主要消费品(XLP)$</a> ，必须消费品上涨是通胀最直接的反映，自从鲍师傅12月5日直接承认通胀，并暗示可能加速Taper，XLP已经连涨了两周。成分股里面PG、COST、PEP、KO、EL等都过去两周都是逆市新高，短期这个通胀预期已经兑现相当充分，应该要开始回调了。但是通胀也不是一时半会儿能下来的，这几个公司和XLP值得大家明年继续关注，等我过几天开始休假了好好整理一下下消费股。同样是消费ETF，可选消费ETF-XLY就跟必消股ETF-XLP差距非常大，主要原因是AMZN和TSLA两个科技股占比太大，接近40%，如果抛去这两个大成分，下面的HD、MC","listText":"老虎的朋友们好，最近要赶年底结算工作略忙，每天只有晚上花一点时间看看盘。这两周市场相当精彩，美联储如“期”加速taper，四巫日也如“期”巨震。终于，今年的bad news都陆续落地，接下来圣诞行情还有吗？ 我个人感觉接下来应该有一波还不错的行情，至于多长时间就只能走着看。值得一提的是巴菲特的<a target=\"_blank\" href=\"https://laohu8.com/S/BRK.A\">$伯克希尔(BRK.A)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$</a> ，股价在周中创了新高。现在Brk的市值跟<a target=\"_blank\" href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$</a> 差不多，6500亿美元左右，NVDA是大家眼里一致预期的下一个万亿俱乐部成员，搞不好Berkshire才是，谁知道呢，大可关注起来。我最近关注消费ETF<a target=\"_blank\" href=\"https://laohu8.com/S/XLP\">$消费品指数ETF-SPDR主要消费品(XLP)$</a> ，必须消费品上涨是通胀最直接的反映，自从鲍师傅12月5日直接承认通胀，并暗示可能加速Taper，XLP已经连涨了两周。成分股里面PG、COST、PEP、KO、EL等都过去两周都是逆市新高，短期这个通胀预期已经兑现相当充分，应该要开始回调了。但是通胀也不是一时半会儿能下来的，这几个公司和XLP值得大家明年继续关注，等我过几天开始休假了好好整理一下下消费股。同样是消费ETF，可选消费ETF-XLY就跟必消股ETF-XLP差距非常大，主要原因是AMZN和TSLA两个科技股占比太大，接近40%，如果抛去这两个大成分，下面的HD、MC","text":"老虎的朋友们好，最近要赶年底结算工作略忙，每天只有晚上花一点时间看看盘。这两周市场相当精彩，美联储如“期”加速taper，四巫日也如“期”巨震。终于，今年的bad news都陆续落地，接下来圣诞行情还有吗？ 我个人感觉接下来应该有一波还不错的行情，至于多长时间就只能走着看。值得一提的是巴菲特的$伯克希尔(BRK.A)$ $伯克希尔B(BRK.B)$ ，股价在周中创了新高。现在Brk的市值跟$英伟达(NVDA)$ 差不多，6500亿美元左右，NVDA是大家眼里一致预期的下一个万亿俱乐部成员，搞不好Berkshire才是，谁知道呢，大可关注起来。我最近关注消费ETF$消费品指数ETF-SPDR主要消费品(XLP)$ ，必须消费品上涨是通胀最直接的反映，自从鲍师傅12月5日直接承认通胀，并暗示可能加速Taper，XLP已经连涨了两周。成分股里面PG、COST、PEP、KO、EL等都过去两周都是逆市新高，短期这个通胀预期已经兑现相当充分，应该要开始回调了。但是通胀也不是一时半会儿能下来的，这几个公司和XLP值得大家明年继续关注，等我过几天开始休假了好好整理一下下消费股。同样是消费ETF，可选消费ETF-XLY就跟必消股ETF-XLP差距非常大，主要原因是AMZN和TSLA两个科技股占比太大，接近40%，如果抛去这两个大成分，下面的HD、MC","images":[{"img":"https://static.tigerbbs.com/d29067b6581247f9ce35181e23d36380","width":"2188","height":"1150"},{"img":"https://static.tigerbbs.com/7108d9566091f4e2a50fc47a7c5c0619","width":"1282","height":"582"},{"img":"https://static.tigerbbs.com/4137e48e4232db1aaf465714045d6d4a","width":"830","height":"302"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693017474","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":6,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":759,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691996697,"gmtCreate":1640109772365,"gmtModify":1640109772365,"author":{"id":"3569745941427325","authorId":"3569745941427325","name":"Guat65","avatar":"https://static.tigerbbs.com/93d2135fbec26685c7a7aa6e923c9ac3","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569745941427325","authorIdStr":"3569745941427325"},"themes":[],"htmlText":"Go","listText":"Go","text":"Go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691996697","repostId":"693578764","repostType":1,"repost":{"id":693578764,"gmtCreate":1640054724293,"gmtModify":1640056006846,"author":{"id":"3527667596890271","authorId":"3527667596890271","name":"Buy_Sell","avatar":"https://static.tigerbbs.com/a5f0ed79a338c758a22e0b4ea13bf9d2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667596890271","authorIdStr":"3527667596890271"},"themes":[],"title":"🚀【12月21日】新能源汽车股重挫，热门中概普跌，今天买点啥？","htmlText":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 港股三大指数涨跌不一，恒指涨0.22%，国指涨0.07%，恒生科技指数跌0.57%。 盘面上，大型科技股继续下跌，<a href=\"https://laohu8.com/S/09999\">$网易-S(09999)$</a> 跌近3%，<a href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 、<a href=\"https://laohu8.com/S/03690\">$美团-W(03690)$</a> 跌超1%，<a href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 等皆有跌幅；内房股与物管股开盘活跃，生物科技股普涨，<a href=\"https://laohu8.com/S/06160\">$百济神州(06160)$</a> 、<a href=\"https://laohu8.com/S/02269\">$药明生物(02269)$</a> 均高开；啤酒股、乳制品、汽车股、体育用品股、航空股普跌，信义玻璃涨近5%，今年净利润同比增长70%-85%。 美股市场 拜登经济支出计划被推迟审议，美股三大指数集体收跌，纳指跌1.24%，道指跌1.23%，标普500指数跌1.14%。 金融股普遍下行，<a href=\"https://laohu8.com/S/GS\">$高盛(GS)$</a> 跌逾3%，<a href=\"https://laohu8.com/S/WFC\">$富国银行(WFC)$</a> 下跌2.8%，<a href=\"https://laohu8.com/S/JPM\">$摩根大通(JPM)$</a> 和<a href=\"https://laohu8.com/S/BAC\">$美</a>","listText":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 港股三大指数涨跌不一，恒指涨0.22%，国指涨0.07%，恒生科技指数跌0.57%。 盘面上，大型科技股继续下跌，<a href=\"https://laohu8.com/S/09999\">$网易-S(09999)$</a> 跌近3%，<a href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 、<a href=\"https://laohu8.com/S/03690\">$美团-W(03690)$</a> 跌超1%，<a href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 等皆有跌幅；内房股与物管股开盘活跃，生物科技股普涨，<a href=\"https://laohu8.com/S/06160\">$百济神州(06160)$</a> 、<a href=\"https://laohu8.com/S/02269\">$药明生物(02269)$</a> 均高开；啤酒股、乳制品、汽车股、体育用品股、航空股普跌，信义玻璃涨近5%，今年净利润同比增长70%-85%。 美股市场 拜登经济支出计划被推迟审议，美股三大指数集体收跌，纳指跌1.24%，道指跌1.23%，标普500指数跌1.14%。 金融股普遍下行，<a href=\"https://laohu8.com/S/GS\">$高盛(GS)$</a> 跌逾3%，<a href=\"https://laohu8.com/S/WFC\">$富国银行(WFC)$</a> 下跌2.8%，<a href=\"https://laohu8.com/S/JPM\">$摩根大通(JPM)$</a> 和<a href=\"https://laohu8.com/S/BAC\">$美</a>","text":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 港股三大指数涨跌不一，恒指涨0.22%，国指涨0.07%，恒生科技指数跌0.57%。 盘面上，大型科技股继续下跌，$网易-S(09999)$ 跌近3%，$阿里巴巴-SW(09988)$ 、$美团-W(03690)$ 跌超1%，$快手-W(01024)$ 等皆有跌幅；内房股与物管股开盘活跃，生物科技股普涨，$百济神州(06160)$ 、$药明生物(02269)$ 均高开；啤酒股、乳制品、汽车股、体育用品股、航空股普跌，信义玻璃涨近5%，今年净利润同比增长70%-85%。 美股市场 拜登经济支出计划被推迟审议，美股三大指数集体收跌，纳指跌1.24%，道指跌1.23%，标普500指数跌1.14%。 金融股普遍下行，$高盛(GS)$ 跌逾3%，$富国银行(WFC)$ 下跌2.8%，$摩根大通(JPM)$ 和$美","images":[{"img":"https://static.tigerbbs.com/8c224c9889536a14f83eca563ae0bb07","width":"-1","height":"-1"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693578764","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"subType":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1621,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}